You have free access to this content

Cancer

Cover image for Cancer

15 December 2005

Volume 104, Issue 12

Pages 2647–2888

  1. Commentary

    1. Top of page
    2. Commentary
    3. Review Articles
    4. Original Articles
    5. Retraction
    1. You have free access to this content
      To achieve (E)quality health care for childhood cancer survivors (pages 2647–2649)

      Brad J. Zebrack and Mark A. Chesler

      Article first published online: 13 NOV 2005 | DOI: 10.1002/cncr.21572

      An expressed goal of psychosocial oncology research and intervention is to facilitate patients' and family members' adjustment to both the short-term and long-term consequences of treatment, recovery, and survivorship. Unfortunately, despite the growing attention to inequalities in health care, little is known regarding the ways in which socioeconomic, racial, and sociocultural status may affect the long-term adjustment and functioning of ill children and their family members.

  2. Review Articles

    1. Top of page
    2. Commentary
    3. Review Articles
    4. Original Articles
    5. Retraction
    1. You have free access to this content
      Does maintenance/consolidation chemotherapy have a role in the management of small cell lung cancer (SCLC)? : A metaanalysis of the published randomized controlled trials (pages 2650–2657)

      Hakan Bozcuk, Mehmet Artac, Mustafa Ozdogan and Burhan Savas

      Article first published online: 13 NOV 2005 | DOI: 10.1002/cncr.21540

      The role of maintenance/consolidation chemotherapy was assessed in the management of small cell lung cancer (SCLC) via a metaanalytic approach.

    2. You have free access to this content
  3. Original Articles

    1. Top of page
    2. Commentary
    3. Review Articles
    4. Original Articles
    5. Retraction
    1. Disease Site

      Breast Disease
      You have free access to this content
      Diagnostic mammography performance and race : Outcomes in Black and White women (pages 2671–2681)

      Bonnie C. Yankaskas and Karminder S. Gill

      Article first published online: 15 NOV 2005 | DOI: 10.1002/cncr.21550

      Black women have lower specificity of diagnostic mammography and, consequently, more unnecessary workups than White women. Black women have higher sensitivity of diagnostic mammography, with cancers that are larger and more advanced than White women.

    2. You have free access to this content
      Angiosarcoma of the breast (pages 2682–2688)

      Stephan A. Vorburger, Yan Xing, Kelly K. Hunt, Gregory E. Lakin, Robert S. Benjamin, Barry W. Feig, Peter W. T. Pisters, Matthew T. Ballo, Lei Chen, Jonathan Trent III, Michael Burgess, Shreyaskumar Patel, Raphael E. Pollock and Janice N. Cormier

      Article first published online: 15 NOV 2005 | DOI: 10.1002/cncr.21531

      Angiosarcoma of the breast is a rare clinical entity that can occur sporadically or after radiation therapy. The 5-year overall survival rate for all patients is 38%.

    3. Genitourinary Disease
      You have free access to this content
      Pilot intervention to enhance sexual rehabilitation for couples after treatment for localized prostate carcinoma (pages 2689–2700)

      Andrea L. Canada, Leah E. Neese, Dawen Sui and Leslie R. Schover

      Article first published online: 17 NOV 2005 | DOI: 10.1002/cncr.21537

      A four-session couples' counseling intervention to address sexual problems (after treatment for prostate carcinoma) was developed and evaluated. For those couples completing the intervention, improvements were noted throughout 3-month follow-up in male overall distress, male global sexual function, female global sexual function, and utilization of medical treatments for erectile dysfunction.

    4. Gynecologic Oncology
      You have free access to this content
      2C4, a monoclonal antibody against HER2, disrupts the HER kinase signaling pathway and inhibits ovarian carcinoma cell growth (pages 2701–2708)

      Noriyuki Takai, Anjali Jain, Norihiko Kawamata, Laura M. Popoviciu, Jonathan W. Said, Sadie Whittaker, Isao Miyakawa, David B. Agus and H. Phillip Koeffler

      Article first published online: 1 NOV 2005 | DOI: 10.1002/cncr.21533

      A monoclonal antibody against HER2, 2C4, is effective in inhibiting the growth of ovarian carcinoma cells in vitro and in vivo. These findings raise the possibility that 2C4 may prove effective in the treatment of ovarian carcinomas.

    5. Head and Neck Disease
      You have free access to this content
      Cyclin D1 gene numerical aberration is a predictive marker for occult cervical lymph node metastasis in TNM Stage I and II squamous cell carcinoma of the oral cavity (pages 2709–2716)

      Kunihiro Myo, Narikazu Uzawa, Ryozo Miyamoto, Itaru Sonoda, Yasuhiro Yuki and Teruo Amagasa

      Article first published online: 1 NOV 2005 | DOI: 10.1002/cncr.21491

      Aberrations in cyclin D1 gene (CCND1) numbers appear to be valuable in identifying patients at high risk of late lymph node metastasis in TNM Stage I and II oral squamous cell carcinomas. Analysis of CCND1 numerical aberrations using fluorescence in situ hybridization on fine-needle aspiration biopsy specimens may be useful in selecting patients for elective cervical lymph node dissection.

    6. Hematologic Malignancies
      You have free access to this content
      Clinical trial of valproic acid and all-trans retinoic acid in patients with poor-risk acute myeloid leukemia (pages 2717–2725)

      Gesine Bug, Markus Ritter, Barbara Wassmann, Claudia Schoch, Thorsten Heinzel, Kerstin Schwarz, Annette Romanski, Oliver H. Kramer, Manuela Kampfmann, Dieter Hoelzer, Andreas Neubauer, Martin Ruthardt and Oliver G. Ottmann

      Article first published online: 17 NOV 2005 | DOI: 10.1002/cncr.21589

      The histone deacetylase inhibitor, valproic acid (VPA), has been shown to overcome the differentiation block in leukemic blasts, an effect enhanced by all-trans retinoic acid (ATRA). In a clinical trial including 26 patients with poor-risk acute myeloid leukemia (AML), treatment with VPA and ATRA resulted in transient disease control in a subset of patients with an AML that had evolved from a myeloproliferative disorder but not in patients with a primary or myelodysplastic syndrome-related AML.

    7. You have free access to this content
      A randomized, postremission comparison of four courses of standard-dose consolidation therapy without maintenance therapy versus three courses of standard-dose consolidation with maintenance therapy in adults with acute myeloid leukemia : The Japan Adult Leukemia Study Group AML97 study (pages 2726–2734)

      Shuichi Miyawaki, Hisashi Sakamaki, Shigeki Ohtake, Nobuhiko Emi, Fumiharu Yagasaki, Kinuko Mitani, Shin Matsuda, Yuji Kishimoto, Yasushi Miyazaki, Norio Asou, Takafumi Matsushima, Masatomo Takahashi, Yoshiaki Ogawa, Sumihisa Honda and Ryuzo Ohno

      Article first published online: 13 NOV 2005 | DOI: 10.1002/cncr.21493

      Conventional postremission therapy for patients with acute myeloid leukemia (three courses of standard-dose consolidation and six courses of maintenance therapy) was replaced successfully by a shorter duration of four courses of standard-dose consolidation therapy without the need for additional maintenance therapy.

    8. You have free access to this content
      Estimating late adverse events using competing risks after autologous stem-cell transplantation in aggressive non-Hodgkin lymphoma patients (pages 2735–2742)

      Rodrigo Ruiz-Soto, Guillaume Sergent, Christian Gisselbrecht, Jerome Larghero, Marjan Ertault, Christophe Hennequin, Julien Manson, Eric de Kerviler, Josette Briere and Nicolas Mounier

      Article first published online: 13 NOV 2005 | DOI: 10.1002/cncr.21492

      Autologous stem-cell transplantation is effective in aggressive non-Hodgkin lymphoma in patients with a poor prognosis, with a 3-year survival estimated at 61%. However, careful long-term follow-up is recommended because of the increase in nonmalignant (34%) and malignant toxicities (3.7%).

    9. You have free access to this content
      The addition of rituximab to fludarabine improves clinical outcome in untreated patients with ZAP-70-negative chronic lymphocytic leukemia (pages 2743–2752)

      Giovanni Del Poeta, Maria Ilaria Del Principe, Maria Antonietta Irno Consalvo, Luca Maurillo, Francesco Buccisano, Adriano Venditti, Carla Mazzone, Antonio Bruno, Laura Gianní, Giovanni Capelli, Francesco Lo Coco, Maria Cantonetti, Valter Gattei and Sergio Amadori

      Article first published online: 14 NOV 2005 | DOI: 10.1002/cncr.21535

      The addition of rituximab to fludarabine in 60 symptomatic, untreated patients with B-cell chronic lymphocytic leukemia (B-CLL) categorized mainly as intermediate Rai stage, achieved both a higher complete remission (CR) rate (78%) and a longer progression-free survival (PFS) rate (68% at 3 yrs). However, significantly shorter CR and PFS rates were obtained in patients who had ZAP-70-positive B-CLL (28 of 60 patients).

    10. You have free access to this content
      Capecitabine combined with gemcitabine (CapGem) as first-line treatment in patients with advanced/metastatic biliary tract carcinoma (pages 2753–2758)

      Jae Yong Cho, Yong Han Paik, Yoon Soo Chang, Se Joon Lee, Dong-Ki Lee, Si Young Song, Jae Bock Chung, Mi-Suk Park, Jeong-Sik Yu and Dong-Sup Yoon

      Article first published online: 17 NOV 2005 | DOI: 10.1002/cncr.21591

      Biliary tract carcinoma is an aggressive cancer, with median survival rarely exceeding 6 months. There is currently no established palliative standard of care. A Phase II trial was conducted to study a combination of oral capecitabine and gemcitabine (CapGem) as first-line therapy in patients with advanced and/or metastatic biliary carcinoma.

    11. Lung Disease
      You have free access to this content
      Phase II study of weekly irinotecan plus capecitabine for chemotherapy-naive patients with advanced nonsmall cell lung carcinoma (pages 2759–2765)

      Ji-Youn Han, Dae Ho Lee, Sung Young Lee, Chun Gun Park, Hyae Young Kim, Hong Gi Lee, Jae Jin Lee, Heung Tae Kim and Jin Soo Lee

      Article first published online: 17 NOV 2005 | DOI: 10.1002/cncr.21563

      A Phase II study was conducted to evaluate the efficacy and toxicity of an irinotecan plus capecitabine combination, a new nonplatinum regimen, in chemonaive patients with advanced nonsmall cell lung carcinoma.

    12. You have free access to this content
      Elderly subgroup analysis of a randomized phase III study of docetaxel plus platinum combinations versus vinorelbine plus cisplatin for first-line treatment of advanced nonsmall cell lung carcinoma (TAX 326) (pages 2766–2774)

      Chandra P. Belani and Frank Fossella

      Article first published online: 15 NOV 2005 | DOI: 10.1002/cncr.21495

      The efficacy and toxicity of first-line platinum-based chemotherapy in patients < 65 and ≥ 65 years was analyzed in cohorts of age from the 1218 nonsmall cell lung carcinoma (NSCLC) patients enrolled in TAX 326, a randomized Phase III study that compared three regimens of platinum-based therapy. Docetaxel–platinum was shown to be an active first-line treatment option with a favorable benefit:risk profile for elderly good performance status patients with advanced NSCLC.

    13. Neuro-Oncology
      You have free access to this content
      Survivin expression and its relation with proliferation, apoptosis, and angiogenesis in brain gliomas (pages 2775–2783)

      Hai-Ning Zhen, Xiang Zhang, Pei-Zhen Hu, Tong-Tao Yang, Zhou Fei, Jian-Ning Zhang, Luo-An Fu, Xiao-Sheng He, Fu-Cheng Ma and Xi-Ling Wang

      Article first published online: 14 NOV 2005 | DOI: 10.1002/cncr.21490

      Survivin was overexpressed and positively correlated with proliferative index, overall daily growth, and microvessel density, whereas it was inversely correlated with the apoptotic index in brain gliomas. Survivin may play an important role in malignant proliferation, antiapoptosis, and angiogenesis of brain gliomas.

    14. You have free access to this content
      Long-term survivors after gamma knife radiosurgery for brain metastases (pages 2784–2791)

      Douglas Kondziolka, Juan J. Martin, John C. Flickinger, David M. Friedland, Adam M. Brufsky, Joseph Baar, Sanjiv Agarwala, John M. Kirkwood and L. Dade Lunsford

      Article first published online: 15 NOV 2005 | DOI: 10.1002/cncr.21545

      Brain metastases were evaluated and outcomes were compared between patients with the best survival and the poorest survival to determine clinical and treatment patterns that potentially were responsible for different outcomes. The results indicated that selected patients who receive effective intracranial and extracranial care can have prolonged, good-quality survival.

    15. You have free access to this content
      Topotecan as a radiosensitizer in the treatment of children with malignant diffuse brainstem gliomas : Results of a French Society of Paediatric Oncology Phase II Study (pages 2792–2797)

      Valerie Bernier-Chastagner, Jacques Grill, Francois Doz, Serge Bracard, Jean Claude Gentet, A. Marie-Cardine, E. Luporsi, G. Margueritte, O. Lejars, V. Laithier, F. Mechinaud, F. Millot, C. Kalifa and Pascal Chastagner

      Article first published online: 1 NOV 2005 | DOI: 10.1002/cncr.21534

      Malignant diffuse brainstem gliomas constitute at least 10% of all childhood brain tumors and continue to have a dismal prognosis regardless of the treatment used. Surgery is not feasible without a high risk of life-threatening neurologic complications and conventional radiotherapy is reported to result in a short median survival. In the current study, the authors evaluated the survival and toxicity observed in children with newly diagnosed brainstem gliomas who were treated with daily radiotherapy with topotecan used as a radiosensitizer.

    16. You have free access to this content
      A population-based description of glioblastoma multiforme in Los Angeles County, 1974–1999 (pages 2798–2806)

      Indro Chakrabarti, Myles Cockburn, Wendy Cozen, Ya-Ping Wang and Susan Preston-Martin

      Article first published online: 15 NOV 2005 | DOI: 10.1002/cncr.21539

      The age-adjusted incidence rates of glioblastoma multiforme (GBM) increased over the past 30 years. Older age, male gender, higher socioeconomic status, and non-Latino white race were associated with increased rates of GBM.

    17. Discipline

      Epidemiology
      You have free access to this content
      BRCA1 and BRCA2 mutations account for a large proportion of ovarian carcinoma cases (pages 2807–2816)

      Tuya Pal, Jenny Permuth-Wey, Judith A. Betts, Jeffrey P. Krischer, James Fiorica, Hector Arango, James LaPolla, Mitchell Hoffman, Martin A. Martino, Katie Wakeley, George Wilbanks, Santo Nicosia, Alan Cantor and Rebecca Sutphen

      Article first published online: 14 NOV 2005 | DOI: 10.1002/cncr.21536

      In this population-based study of incident epithelial ovarian carcinomas, the authors demonstrated that the frequency of BRCA1 and BRCA2 mutations among women with ovarian carcinoma was higher than reported previously. The current data suggested that it may be reasonable to offer genetic counseling to any woman with invasive epithelial ovarian carcinoma, because family history is not sufficiently accurate to predict the presence or absence of a mutation.

    18. You have free access to this content
      Reduced cancer incidence among patients with schizophrenia (pages 2817–2821)

      Yoram Barak, Anat Achiron, Matilda Mandel, Ilona Mirecki and Dov Aizenberg

      Article first published online: 15 NOV 2005 | DOI: 10.1002/cncr.21574

      The incidence of cancer in patients with schizophrenia has been conversely reported to be higher, lower, or similar to that in the general population. The effects of lifestyle factors such as excess smoking, exposure to neuroleptic medications, and genetic factors that may influence the incidence of cancer in this group are not clear. The current study was conducted to evaluate the frequency of cancer in a large cohort of patients with schizophrenia.

    19. Medical Oncology
      You have free access to this content
      Risk factors for chemotherapy-associated venous thromboembolism in a prospective observational study (pages 2822–2829)

      Alok A. Khorana, Charles W. Francis, Eva Culakova and Gary H. Lyman

      Article first published online: 13 NOV 2005 | DOI: 10.1002/cncr.21496

      Symptomatic venous thromboembolism is a frequent complication of chemotherapy. An elevated prechemotherapy platelet count is associated with a nearly threefold greater risk of developing venous thromboembolism.

    20. Pathology
      You have free access to this content
      Pancreatic juice cytology in the diagnosis of intraductal papillary mucinous neoplasm of the pancreas : Significance of sampling by peroral pancreatoscopy (pages 2830–2836)

      Taketo Yamaguchi, Yoshihiko Shirai, Takeshi Ishihara, Kentarou Sudo, Akihiko Nakagawa, Hiroshi Ito, Masaru Miyazaki, Fumio Nomura and Hiromitsu Saisho

      Article first published online: 14 NOV 2005 | DOI: 10.1002/cncr.21565

      The examination of pancreatic juice cytology could hypothetically contribute to the establishment of a definite diagnosis of malignant intraductal papillary mucinous neoplasm (IPMN) of the pancreas. The current study was conducted to assess the diagnostic value of pancreatic juice cytology in patients with IPMN and to examine the usefulness of peroral pancreatoscopy in sampling pancreatic juice.

    21. Pediatric Oncology
      You have free access to this content
      The impact of early resection of primary neuroblastoma on the survival of children older than 1 year of age with stage 4 disease : The St. Jude Children's Research Hospital experience (pages 2837–2846)

      Lisa M. McGregor, Bhaskar N. Rao, Andrew M. Davidoff, Catherine A. Billups, Suradej Hongeng, Victor M. Santana, D. Ashley Hill, Christine Fuller and Wayne L. Furman

      Article first published online: 15 NOV 2005 | DOI: 10.1002/cncr.21566

      This retrospective study found that patients older than 1 year of age with metastatic neuroblastoma who underwent gross total resection of the primary tumor before chemotherapy had a significant survival advantage compared with patients who underwent gross total resection after induction chemotherapy. Prospective studies are warranted to confirm the value of this treatment approach.

    22. You have free access to this content
      Transdermal fentanyl in the management of children with chronic severe pain : Results from an international study (pages 2847–2857)

      Julia C. Finkel, Allen Finley, Christine Greco, Steve J. Weisman and Lonnie Zeltzer

      Article first published online: 14 NOV 2005 | DOI: 10.1002/cncr.21497

      In the current study, transdermal fentanyl was found to be a safe and well tolerated alternative to oral opioid treatment for children ages 2–16 years who were previously exposed to opioid therapy.

    23. You have free access to this content
      L-asparaginase as a marker of chemotherapy dose modification in children with acute lymphoblastic leukemia (pages 2858–2861)

      Jacques Baillargeon, Anne-Marie Langevin, Margaret Lewis, Paul J. Thomas, Judith Mullins, John Dugan and Brad H. Pollock

      Article first published online: 15 NOV 2005 | DOI: 10.1002/cncr.21584

      The objective of the current study was to compare chemotherapy dose modification in obese (a body mass index [BMI] > 95%) and nonobese (a BMI ≤ 95%) pediatric patients with acute lymphoblastic leukemia (ALL). Overall, obese ALL patients exhibited a 7% decrease in the mean relative modification of L-asparaginase during induction chemotherapy compared with their nonobese counterparts.

    24. You have free access to this content
      Phase II study of high-dose chemotherapy before radiation in children with newly diagnosed high-grade astrocytoma : Final Analysis of Children's Cancer Group Study 9933 (pages 2862–2871)

      Tobey J. MacDonald, Edward B. Arenson, Joann Ater, Richard Sposto, Herbert E. Bevan, Janet Bruner, Melvin Deutsch, Elizabeth Kurczynski, Thomas Luerssen, Patricia McGuire-Cullen, Richard O'Brien, Narayan Shah, Paul Steinbok, John Strain, John Thomson, Emi Holmes, Gilbert Vezina, Allan Yates, Peter Phillips and Roger Packer

      Article first published online: 28 NOV 2005 | DOI: 10.1002/cncr.21593

    25. Psychological Oncology
      You have free access to this content
      Psychiatric disorders and mental health service use in patients with advanced cancer : A report from the coping with cancer study (pages 2872–2881)

      Nina S. Kadan-Lottick, Lauren C. Vanderwerker, Susan D. Block, Baohui Zhang and Holly G. Prigerson

      Article first published online: 14 NOV 2005 | DOI: 10.1002/cncr.21532

      Advanced cancer patients who are vulnerable to psychiatric illness are receptive to utilizing mental health services, yet only 45% with a major psychiatric disorder accessed mental health services. Cancer patients who had discussed psychological concerns with mental health staff and white patients were more likely than others to receive mental health services.

    26. Symptom Control and Palliative Care
      You have free access to this content
      Extrapulmonary tuberculosis active infection misdiagnosed as cancer : Mycobacterium tuberculosis disease in patients at a comprehensive cancer center (2001–2005) (pages 2882–2887)

      Gabriel M. Aisenberg, Kalen Jacobson, Roy F. Chemaly, Kenneth V. Rolston, Isaam I. Raad and Amar Safdar

      Article first published online: 21 OCT 2005 | DOI: 10.1002/cncr.21541

      Extrapulmonary tuberculosis was common in younger patients with active Mycobacterium tuberculosis infection receiving care at the study tertiary care cancer center. These infections were often initially misdiagnosed as cancer and a delay in correct diagnosis was associated with increased risk of infection-associated death.

  4. Retraction

    1. Top of page
    2. Commentary
    3. Review Articles
    4. Original Articles
    5. Retraction
    1. You have free access to this content

SEARCH

SEARCH BY CITATION